Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.39 |
| ▸ | SLC2A9 | Q9NRM0 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 7/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | GALK1 | P51570 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616045 | 1.00 | SLC22A12 (0.39) | SLC22A12SLC2A9AKR1C3APEX1POLB | |
| SCHEMBL16395615 | 0.83 | SLC22A12 (0.34) | SLC22A12SLC2A9 | |
| SCHEMBL9960738 | 0.77 | POLB (0.35) | POLBAPAF1TDP2NSD2CYP1A2 | |
| SCHEMBL9960569 | 0.76 | APEX1 (0.50) | AKR1C3APEX1POLBCYP2C9 | |
| SCHEMBL2530115 | 0.74 | AKR1B1 (0.41) | POLBCYP1A2MAPT | |
| SCHEMBL5138671 | 0.74 | KDM4E (0.39) | SLC22A12SLC2A9AKR1C3APEX1POLB | |
| SCHEMBL28015994 | 0.72 | ACHE (0.34) | POLBCYP1A2CYP2C19 | |
| SCHEMBL5484988 | 0.72 | POLB (0.42) | AKR1C3APEX1POLBMAPTKMT2A | |
| SCHEMBL2426303 | 0.72 | KEAP1 (0.44) | APEX1CYP1A2MAPT | |
| SCHEMBL17060190 | 0.71 | PAM (0.40) | KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676698-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2017-06-13 | — | — | US | claimed |
| CN-103443066-A | Ingenol-3-acylates I | LEO LABORATIRIES LTD | 2013-12-11 | — | — | CN | claimed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | claimed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| EP-3640236-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2020-04-22 | — | — | EP | disclosed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | disclosed |
| US-10172306-B2 | Production of ingenol, ingenol esters and/or tiglian-3-one derivatives by euphorbiaceae plant cell suspension cultures | PHYTON HOLDINGS, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180042194-A1 | PRODUCTION OF INGENOL, INGENOL ESTERS AND/OR TIGLIAN-3-ONE DERIVATIVES BY EUPHORBIACEAE PLANT CELL SUSPENSION CULTURES | PHYTON HOLDINGS, LLC (US) | 2018-02-15 | — | — | US | disclosed |
| US-9676698-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2017-06-13 | — | — | US | disclosed |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2016-09-29 | — | — | US | disclosed |
| US-9416084-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2016-08-16 | — | — | US | disclosed |
| CN-103443066-A | Ingenol-3-acylates I | LEO LABORATIRIES LTD | 2013-12-11 | — | — | CN | disclosed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | disclosed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | disclosed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | disclosed |
| CN-103119016-A | Method for preparing ingenol-3-angelate | LEO PHARMA AS | 2013-05-22 | — | — | CN | disclosed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324600-A1 | INGENOL-3-ACYLATES I | CXCL8, MMP8, CASP8 | SLC22A12 3968/4885SLC2A9 4285/4885AKR1C3 70/4885 |
| US-10172306-B2 | Production of ingenol, ingenol esters and/or tiglian-3-one derivatives by euphorbiaceae plant cell suspension cultures | LANCL2, ELOVL3, NFATC1 | SLC22A12 1917/4885SLC2A9 1385/4885AKR1C3 1243/4885 |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | SLC22A12 4712/4885SLC2A9 4453/4885AKR1C3 188/4885 |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | SLC22A12 4712/4885SLC2A9 4453/4885AKR1C3 188/4885 |
| US-20180042194-A1 | PRODUCTION OF INGENOL, INGENOL ESTERS AND/OR TIGLIAN-3-ONE DERIVATIVES BY EUPHORBIACEAE PLANT CELL SUSPENSION CULTURES | ELOVL3, LANCL2, ICOS | SLC22A12 1810/4885SLC2A9 1319/4885AKR1C3 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.